Frustrated Eli Lilly may have to settle for a lonely last-place finish in the blockbuster CDK 4/6 race
A frustrated Eli Lilly will have to wait patiently for its closely-watched Phase III study of the CDK 4/6 breast cancer drug abemaciclib to wrap …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
